Immunotherapy has produced some genuinely remarkable results for certain cancer patients, sometimes leading to long-term remission in cases that previously had limited options. At the same time, immunotherapy treatment does not work equally well for everyone, even among patients with the same type and stage of cancer. Understanding why can help set more realistic expectations if this treatment is part of your care plan.
Immunotherapy Depends on Your Immune System, Not Just Your Cancer
Unlike chemotherapy, which works fairly consistently by targeting rapidly dividing cells, immunotherapy relies on your own immune system’s ability to recognize and respond to cancer cells. Since immune function varies significantly between individuals based on genetics, overall health, age, and even the specific characteristics of their cancer, response to immunotherapy naturally varies as well.
Key Factors That Influence Immunotherapy Response
Tumor Biomarkers
Certain biological markers on cancer cells, such as specific protein expressions, strongly influence how well a tumor responds to immunotherapy. Patients with higher levels of these markers often respond better than those without them, which is why biomarker testing is frequently done before starting treatment.
Tumor Mutational Burden
Cancers with a higher number of genetic mutations tend to produce more abnormal proteins that the immune system can recognize as foreign, which generally makes them more responsive to immunotherapy compared to cancers with fewer mutations.
Overall Immune System Health
Patients with a generally stronger, more functional immune system tend to respond better to treatments designed to activate that system. Factors like nutritional status, existing health conditions, and even certain medications can influence overall immune function during treatment.
The Tumor’s Microenvironment
The environment directly surrounding a tumor can either support or suppress immune activity. Some tumors create a highly suppressive environment that makes it harder for immunotherapy to work effectively, even when other factors seem favorable.
Cancer Type and Stage
Some cancer types have simply shown stronger overall response rates to immunotherapy in clinical research than others. Earlier stage cancers, in many cases, also tend to respond better than more advanced, heavily pretreated disease.
Reviewing How Immunotherapy Works to Understand the Variability
Reviewing how immunotherapy works helps clarify why these individual differences matter so much. Since the treatment depends on activating a biological process rather than delivering a direct, uniform chemical attack on cancer cells, the variability in how each patient’s immune system responds becomes a central factor in treatment outcomes.
What This Means If Immunotherapy Is Part of Your Treatment Plan
If your oncologist recommends immunotherapy, it is usually based on specific testing that suggests a reasonable likelihood of response for your particular cancer. That said, even with favorable markers, response can still vary, which is why close monitoring throughout treatment matters so much. If initial results are not as expected, this does not necessarily mean the overall treatment strategy has failed. It may simply mean an adjustment to the approach is needed.
Understanding What Is Immunotherapy Realistically Capable Of
Understanding what is immunotherapy realistically capable of, given these variables, helps patients approach treatment with informed expectations rather than assuming uniform results based on other patients’ experiences they may have heard about.
The Role of Supportive Care During Immunotherapy
Given the individualized nature of immunotherapy response, supportive cancer care can help patients manage the physical and emotional demands of treatment while their oncology team monitors and adjusts the approach as needed based on how their specific case is responding.
How Dr. Tarang Krishna Supports Patients Through This Uncertainty
Dr. Tarang Krishna works with patients undergoing immunotherapy to provide supportive guidance through the uncertainty that comes with variable treatment response, helping manage side effects and overall wellbeing alongside the primary oncology team’s monitoring and adjustments.
Getting Started
If you are considering or currently undergoing immunotherapy (CAM), understanding the factors that influence how well it works for your specific case can help you approach the treatment journey with realistic, informed expectations.
Frequently Asked Questions
Why does immunotherapy work for some patients but not others with the same cancer?
Response depends on individual factors like tumor biomarkers, mutational burden, and overall immune system health, which vary significantly between patients even with the same diagnosis.
Can I be tested to see if immunotherapy will work for me?
Yes, biomarker testing is commonly used before starting treatment to assess the likelihood of a favorable response, though it cannot guarantee results with complete certainty.
If immunotherapy is not working, does that mean my case is hopeless?
No, it often means the treatment approach needs adjustment. Your oncology team may recommend a different combination or alternative treatment based on how your case responds.
Does a healthier immune system always mean better immunotherapy response?
Generally, better overall immune function supports a more favorable response, though other factors like tumor biology also play a significant role in the outcome.
How long does it take to know if immunotherapy is working?
This varies by cancer type and treatment, but initial assessments are often made after a few cycles of treatment through imaging and other monitoring methods.
Can supportive care improve how well immunotherapy works?
Supportive care does not directly change biological response to immunotherapy, but it can help patients tolerate treatment better and maintain overall strength throughout the process.
